The design of other VEGFR dual inhibitors (VEGFR/BRAF, VEGFR/FAK, VEGFR/PI3K, VEGFR/Src, VEGFR/AKT, VEGFR/HER2, VEGFR/c-Met, and VEGFR/FGFR-1/BRAF) indicates a clear trend toward polypharmacology, supported by the implementation of pharmacophore fusion and hybridization strategies [ 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 ].
← all excerpts
Current Computational Approaches for the Discovery of Novel Anticancer Agents Targeting VEGFR and SIRT Signaling Pathways.
1
—
—